ArticleCureus2024
Quality Assessment of Functional Claims of Salacia-Derived Salacinol-Containing Foods.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Functional claim-associated foods contain raw materials that contribute to enhancing health in Japan. However, certain foods with functional claims fail to meet the disintegration test (DT) criteria of the Japanese Pharmacopoeia (JP). Objective This study assessed the quality of tablet-type, functional claim-associated foods containing Salacia-derived salacinol, using DT and weight variation (WV) tests. Methods DT and WV were conducted on functional foods (A, B, and C) sourced from three companies using samples stored either at room temperature (RT: 22-27 ℃) or in an incubator at 40 ± 2 °C and 75% ± 5% in relative humidity accelerated conditions (AC) for one, two, and four weeks, respectively. Results Samples A and C were compliant under all WV test conditions, whereas sample B was compliant except when stored in AC. DT results indicated compliance for sample A upon immediate opening and on storing for two and four weeks at RT, sample B for four weeks at RT, and sample C upon immediate opening, all AC, and stored for two and four weeks at RT. Conclusions Varied disintegration times may affect the release of functionally active ingredients into the body and their absorption from the gastrointestinal tract, potentially compromising their intended health benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.